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Research
Occupational studies have repeatedly demon­
strated that blood lead levels (BLL) > 40 µg/dL 
are associated with increased risk of elevated 
blood pressure (BP) (reviewed by Navas­Acien 
et al. 2007). A recent meta­analysis reported 
that a 2­fold increase in BLL was associated 
with a 1.0­mmHg and a 0.6­mmHg increase 
in systolic and diastolic BP, respectively 
(Nawrot et al. 2002). Previous studies have 
demonstrated associations between low­level 
lead exposure and increased BP (Den Hond 
et al. 2002; Nash et al. 2003; Navas­Acien 
et al. 2004; Nordberg et al. 2000; Pirkle et al. 
1985; Vupputuri et al. 2003), but the results 
have been uneven, suggesting that other bio­
logical factors (e.g., genetic and race/ethnicity) 
may also be operating. 
The δ­aminolevulinic acid dehydratase 
(ALAD) enzyme catalyzes the second step 
in heme biosynthesis and is known to be 
the major carrier protein for lead in blood 
(Bergdahl et al. 1997). ALAD, which in 
humans is encoded by a single gene local­
ized to the chromosome 9q34 region, is 
a polymorphic enzyme with two co­domi­
nantly expressed alleles, ALAD1 and ALAD2 
(dbSNP ID rs1800435) (Battistuzzi et al. 
1981). The difference between these two 
alleles lies in a single G→C transversion 
mutation of nucleotide 177 in ALAD2; the 
allozyme resulting from the ALAD2 allele 
contains the substitution of a neutral aspar­
agine for a positively charged lysine at residue 
59 (Wetmur et al. 1991). Three differently 
charged allozymes, ALAD1­1, 1­2, and 2­2, 
result from the expression of the ALAD1 and 
ALAD2 alleles, which have different affinities 
for lead (Bergdahl et al. 1997). The frequen­
cies of the ALAD1 and ALAD2 alleles in sev­
eral white populations have been estimated 
to be 0.9 and 0.1, respectively, whereas Asian 
and African populations have lower ALAD2 
allele frequencies (Kelada et al. 2001). It is 
well known that individuals vary greatly in 
susceptibility to lead toxicity, and genetic sus­
ceptibility has often been cited as the prob­
able cause for such variation (Kelada et al. 
2001). In a review of occupational studies in 
which lead exposure was relatively high, the 
rs1800435 polymorphism in the ALAD gene 
was positively associated with BLL; however, 
no association has been found between ALAD 
and BLL among environmentally exposed 
adults with BLL < 10 µg/dL (Scinicariello 
et al. 2007).
Few studies have addressed the relation­
ship between ALAD genotype status and BLL 
and BP, and the results have been inconclu­
sive. A study conducted among Korean lead 
smelter workers (n = 798; mean BLL = 32.0 
µg/dL) showed that ALAD2 carriers had a sta­
tistically significantly increased systolic BP at 
occupational lead exposure levels compared 
with ALAD1 homozygous carriers (Lee et al. 
2001). A previous study conducted among 691 
members of a construction trade union (mean 
BLL = 7.78 µg/dL) found that systolic BP and 
diastolic BP were increased in ALAD2 carriers 
compared with members homozygous for the 
ALAD1 allele. This difference, however, was 
not statistically significant (Smith et al. 1995).
Currently, the Centers for Disease Control 
and Prevention (CDC) designates 10 µg/dL as 
a BLL of concern and has formulated guide­
lines for environmental and educational inter­
vention in children at this level (CDC 2002). 
However, no corresponding CDC guidance 
exists for BLL measured in adults.
The objective of our study is to determine, in 
a large, nationally representative sample [Third 
National Health and Nutrition Examination 
Survey (NHANES III), 1988–1994], whether 
the relationship between BP and lead exposure 
differs by ALAD genotype status.
Materials and Methods
NHANES III is a survey representative of the 
civilian, noninstitutionalized U.S. population 
and was conducted in 1988–1994 (National 
Center for Health Statistics 1994). The sample 
was selected through a complex, multistage 
probability design and included oversampling 
of non­Hispanic blacks, Mexican Americans, 
children, and the elderly (National Center 
for Health Statistics 1994). Sample weights 
account of differential probability of selec­
tion and nonresponse and are poststratified 
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to census population estimates. Individuals 
participated in an interview conducted at 
home and also received an extensive physical 
examination performed at a mobile examina­
tion center (MEC), which included blood and 
urine collection. The total number of partici­
pants from the second phase of NHANES III 
(1991–1994) was 16,530. The NHANES III 
DNA bank contains specimens from 7,159 
participants ≥ 12 years of age who were exam­
ined during the second phase of NHANES III 
(1991–1994) (Chang et al. 2009). The sam­
ple weights were derived from the NHANES 
III phase 2 MEC­examined sample weights, 
and they were recalculated using previously 
described methods (Lohr 1999) for the 7,159 
participants for whom DNA was available to 
avoid nonresponse bias for the NHANES III 
genetic data.
The present study included participants 
in the NHANES III DNA bank ≥ 17 years of 
age and self­reported as non­Hispanic white, 
non­Hispanic black, or Mexican American 
(n = 6,016). Further details regarding the 
NHANES III DNA bank have been previ­
ously described (Chang et al. 2009).
Definitions and measurements of variables. 
Outcome variables. Hypertension status and 
two BP measures (systolic and diastolic BP) 
were the outcome measures. Hypertension 
was defined as self­reported current use of an 
antihypertensive medication, systolic BP of 
≥ 140 mmHg, or diastolic BP of ≥ 90 mmHg. 
Systolic and diastolic BP levels were examined 
for persons not currently taking antihyperten­
sive medication. Hypertension was treated as a 
dichotomous variable, and the two BP meas­
ures were treated as continuous variables.
BP for individual participants was cal­
culated as the average of all available meas­
urements (maximum = 6) from the home 
interview and MEC.
BP measurements were performed in the 
MEC by the physician on children (5–19 
years of age) and adults (≥ 20 years of age); 
the interviewers took measurements on adults 
only (≥ 17 years of age) in the household. 
More details can be found at the reference 
manual of BP quality control program (CDC 
1991).
Other variables. BLL was determined 
using graphite furnace atomic absorption 
spectrophotometry. Total serum calcium 
was measured by ion­selective electrodes. 
Serum creatinine was measured by the modi­
fied kinetic Jaffe reaction using a Hitachi 
737 analyzer (Boehringer Mannheim Corp., 
Indianapolis, IN). Glycosylated hemoglobin 
(HbA1C) was measured using ion exchange 
chromatography. Details of the laboratory pro­
tocols for each of these measures can be found 
on the CDC National Center for Health 
Statistics Web site (Gunter et al. 1996).
Phenotypic covariates analyzed in the 
regression analysis included the continuous 
variables of body mass index (BMI, calculated 
as weight in kilograms divided by the square of 
height in meters) and serum creatinine   levels 
and the categorical variables of age (17–39, 
40–59, and ≥ 60 years), sex, education (< high 
school, completed high school, some college), 
cigarette smoking history (current, former, or 
never), and weekly alcohol intake (none, < 4, 
and ≥ 4 drinks per week).
ALAD genotyping methods. The ALAD 
polymorphism was genotyped at the Core 
Genotyping Facility, National Cancer 
Institute, National Institutes of Health 
(Bethesda, MD), using TaqMan assays 
(Applied Biosystems, Foster City, CA). 
Detailed information on genotyping methods 
and quality control methods have been previ­
ously described (Chang et al. 2009). Briefly, 
the quality of the genetic data was assured 
through the use of water controls, DNA sam­
ples with known genotypes, blinded repli­
cates of approximately 6% of samples, and 
tests for deviations from Hardy–Weinberg 
  proportions.
Statistical analysis. We used multivariable 
logistic and linear regression to examine the 
relationships among hypertension (and BP 
measures), BLL, and the ALAD polymorphism 
in non­Hispanic white, non­Hispanic black, 
and Mexican­American race/ethnicity catego­
ries. Participants were categorized into BLL 
quartiles based on the weighted population 
distribution. The ALAD polymorphism was 
assessed assuming a dominant model (ALAD1/
ALAD1 vs. ALAD1/ALAD2 and ALAD2/
ALAD2) where the homozygous major allele 
(ALAD1) was the reference group and the 
heterozygous plus homozygous for the minor 
allele (ALAD2) was the evaluated group.
Models were analyzed separately for the 
three outcomes of interest as indicated above. 
Effect modification by ALAD in the rela­
tionship between blood levels and hyperten­
sion outcome was examined through models 
stratified by BLL quartiles: BLL = 0.7–1.4, 
1.5–2.3. 2.4–3.7. 3.8–52.9 µg/dL. Also, 
analyses were run excluding from the fourth 
Table 1. Weighted characteristics of the participants from the NHANES III DNA bank stratified by race/
ethnicity.
Characteristic  All participants
Non-Hispanic 
whites 
Non-Hispanic 
blacks 
Mexican 
Americans
No. 6,016 2,387 1,670 1,746
BLL (µg/dL) 2.99 ± 0.09 2.87 ± 0.09 3.59 ± 0.20 3.33 ± 0.11
ALAD1-2/2-2 (%) 13.6  15.6   2.6   8.8
BP (mmHg)
Systolic BP 119.0 ± 0.39 119 ± 0.48 120.2 ± 0.43 116.9 ± 0.64
Diastolic BP 73.5 ± 0.27 73.5 ± 0.27 74.4 ± 0.47 71.9 ± 0.53
Systolic BP ≥ 140 mmHg (%)a   9.2    9.3 10.4   6.3
Diastolic BP ≥ 90 mmHg (%)a   5.4    5.1   8.8   4.1
Hypertension (% yes)b 22.7  22.6 28.4 13.8
Race/ethnicity (%) 
Non-Hispanic white 81.6 
Non-Hispanic black 12.4 
Mexican American   6.0 
Age [years (%)]
17–39 47.0 44.4 55.8 65.4
40–59 30.9  31.7 28.3 25.1
≥ 60 22.1  23.9 15.9   9.5
Female (%) 52.1  51.9 55.2 48.5
BMI (kg/m2) 26.7 ± 0.16 26.5 ± 0.18 28.0 ± 0.24 27.6 ± 0.10
Smoking history (%)
Current smoker 25.8  25.6 29.9 20.7
Former smoker 25.3  27.3 14.0 20.3
Never smoker 48.9  47.1 56.1 59.1
Alcohol use (%) 
None 47.4 45.9 55.6 50.8
< 4 drinks/week 27.8  28.8 21.7 25.9
≥ 4 drinks/week 24.8  25.3 22.8 23.4
Education (%)
< High school 22.7  18.6 33.3 56.9
Completed high school 34.6  34.7 38.4 26.2
Some college 42.7  46.7 28.3 16.9
Serum creatinine (mg/dL) 0.86 ± 0.01 0.86 ± 0.01 0.92 ± 0.01 0.77 ± 0.01
Serum calcium (mg/dL) 9.19 ± 0.03 9.18 ± 0.03 9.22 ± 0.03 8.19 ± 0.04
Hematocrit (%) 42.1 ± 0.12 42.4 ± 0.12 40.6 ± 0.16 42.5 ± 0.15
Log glycosylated hemoglobin (%) 1.68 ± 0.01 1.67 ± 0.01 1.71 ± 0.01 1.69 ± 0.01
Values are percent or mean ± SE.
aSubject with systolic BP of ≥ 140 mmHg or diastolic BP of ≥ 90 mmHg not currently treated for hypertension. bHyperten-
sion defined as a self-report of currently taking antihypertensive medication, systolic BP of ≥ 140 mmHg, or diastolic BP 
of ≥ 90 mmHg.ALAD alleles, lead, and hypertension in NHANES III
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quartile individuals with BLL > 10.0 µg/dL 
(BLL range, 3.8–10.0 µg/dL).
We used the multivariable linear regres­
sion to examine the relationships among BP 
measures (systolic and diastolic BP), ALAD 
genotype status, log­transformed BLL, and the 
interaction term between log­transformed BLL 
and ALAD genotype status. The BLLs were 
log­transformed (natural logarithms) because 
the lead levels in blood were right skewed. The 
change in BP associated with a doubling of the 
BLL was calculated by multiplying the regres­
sion coefficient by 0.69 (Nawrot et al. 2002).
We conducted multivariable regression 
models adjusting for the potential risk fac­
tors age, sex, education, smoking status, alco­
hol intake, BMI, serum creatinine levels (as a 
marker of kidney function), serum calcium, 
glycosylated hemoglobin (a time­integrated 
marker of average glycemia during the previ­
ous 3 months), and hematocrit. These risk 
factors have previously shown to be associ­
ated with BP and hypertension (Burt et al. 
1995) and with lead and BP (Nash et al. 2003; 
Vupputuri et al. 2003), including hematocrit 
(Hense et al. 1993) and alcohol intake (Hense 
et al. 1993, 1994).
Statistical analyses were performed using 
SAS version 9.1 (SAS Institute Inc., Cary, 
NC) and SAS­callable SUDAAN version 9.01 
(Research Triangle Institute, Research Triangle 
Park, NC) to account for the NHANES 
III complex sample design. p­Values from 
Satterthwaite statistics were presented at the 
significance level of 0.05.
Results
Table 1 illustrates the characteristics of partici­
pants (n = 6,016) from the NHANES III DNA 
bank weighted to be representative of the U.S. 
population. The mean age of the population 
was 44 years (data not shown). Approximately 
52% of individuals were female. Non­Hispanic 
whites accounted for 81.6% of the total popu­
lation. Approximately 43%, 47%, and 49% 
of the people reported that they had attended 
some college, never used alcohol, and never 
smoked, respectively. The mean (± SE) for 
systolic BP was 119.0 ± 0.39 mmHg and 
for diastolic BP was 73.5 ± 0.27 mmHg. 
Hypertension was observed in 22.7% of the 
population. For those not currently treated 
for hypertension, 9.2% and 5.5%, had systolic 
(≥ 140 mmHg) and diastolic (≥ 90 mmHg) 
hypertension, respectively. We estimated the 
mean (± SE) BLL to be 2.98 ± 0.09 µg/dL. 
Table 1 also summarizes the characteristic of 
the study participants by race/ethnicity.
Table 2 summarizes the characteristics 
of the study participants by BLL quartile. 
Individuals in the highest BLL quartiles tended 
to be older, male, current smokers, regular 
drinkers, less educated, and more likely to 
have hypertension and to have increased serum 
creatinine, hematocrit, and systolic and dia­
stolic levels of BP. 
Table 3 presents the ALAD genotypes and 
mean BLL by ALAD genotype and by BLL 
quartile for each of the three major race/  ethnic 
groups in the United States. ALAD2 carri­
ers comprised 13.6% of the total population, 
15.6% (370 of 2,017) of non­Hispanic 
whites, 2.6% (49 of 1,621) of non­Hispanic 
blacks, and 8.8% (137 of 1,609) of Mexican 
Americans. Among participants with the 
ALAD1-1 genotype, we observed a slightly 
higher BLL for all race/ethnic subgroups com­
pared with the participants with ALAD1-2 
Table 2. Characteristics by BLL quartile of adults ≥ 17 years of age participating in the NHANES III DNA bank.
Characteristic
Quartile 1 
(0.7–1.4 µg/dL) 
Quartile 2 
(1.5–2.3 µg/dL)
Quartile 3 
(2.4–3.7 µg/dL)
Quartile 4 
(3.8–52.9 µg/dL)
p-Value 
for trend
Median BLL (µg/dL)   0.70   1.90   3.00   5.00 
ALAD2 carriers, 1-2/2-2 (%) 15.1 14.2 11.6 13.5
BP (mmHg)
Systolic BP 113.5 ± 0.41 116.9 ± 0.46 121.1 ± 0.81 124.6 ± 0.58 < 0.001
Diastolic BP  71.6 ± 0.45 73.0 ± 0.42 74.3 ± 0.44 75.3 ± 0.50 < 0.001
Systolic BP ≥ 140 mmHg (%)a    3.0    7.2  11.9  15.1  < 0.001
Diastolic BP ≥ 90 mmHg (%)a   3.2    4.6    6.2    8.0  < 0.001
Hypertension, yes (%)b 10.9  18.4  27.4 33.1  < 0.001
Race (%)
Non-Hispanic white 83.7  83.5  81.8  77.6 
Non-Hispanic black 10.8  11.4  12.1  15.4  < 0.01
Mexican American   5.6    5.1    6.1   7.0 
Age [years (%)]
17–39 71.3  50.6  39.7  28.9 
40–59 21.6  32.6  32.8  35.5  < 0.001
≥ 60   7.1  16.9  27.5  35.6 
Sex (%)
Male 26.6 40.2  53.8 69.1 < 0.001
Female 73.4  59.8 46.2  30.9
BMI (kg/m2) 26.66 ± 0.47 26.70 ± 0.21 26.70 ± 0.21 26.63 ± 0.22 0.9
Smoking history (%)
Current 14.2 21.7 29.8 36.6
Former  19.16 25.4 23.9 32.1 < 0.001
Never 66.7 52.9 46.3 31.3
Alcohol use (%)
None 52.5 50.8 46.0 40.6
< 4 drinks/week 31.6 28.4 27.2 24.3 < 0.001
≥ 4 drinks/week 15.9 20.9 26.8 35.2
Education (%)
< High school 16.6 15.6 25.7 32.2
Completed high school 36.7 33.1 34.2 34.7 < 0.001
Some college 46.7 51.2 40.2 33.1
Serum creatinine (mg/dL) 0.78 ± 0.01 0.83 ± 0.01 0.88 ± 0.01 0.94 ± 0.01 < 0.001
Serum calcium (mg/dL) 9.15 ± 0.03 9.17 ± 0.03 9.22 ± 0.03 9.21 ± 0.04 0.02
Log glycosylated hemoglobin (%) 1.64 ± 0.01 1.67 ± 0.01 1.70 ± 0.01 1.70 ± 0.01 < 0.001
Hematocrit (%)  40.72 ± 0.24 41.72 ± 0.14 42.83 ± 0.20 43.19 ± 0.16 < 0.001
Values are percent or mean ± SE.
aSubject with systolic BP of ≥ 140 mmHg or diastolic BP of ≥ 90 mmHg not currently treated for hypertension. 
bHypertension defined as a self-report of currently taking antihypertensive medication, systolic BP of ≥ 140 mmHg, or 
diastolic BP of ≥ 90 mmHg.
Table 3. Prevalence of ALAD genotypes and BLL (mean ± SE) by race/ethnicity and by BLL quartile.
BLL quartile
Genotype Percent  BLL 
Quartile 1 
(0.7–1.4 µg/dL)
Quartile 2 
(1.5–2.3 µg/dL)
Quartile 3 
(2.4–3.7 µg/dL)
Quartile 4 
(3.8–52.9 µg/dL) 
All participants
ALAD1-1 86.4  3.01 ± 0.09 0.94 ± 0.02 1.88 ± 0.01 3.00 ± 0.04 5.92 ± 0.12
ALAD1-2/2-2 13.6  2.84 ± 0.14 0.92 ± 0.03 1.84 ± 0.03 2.90 ± 0.04 5.72 ± 0.20
Non-Hispanic whites
ALAD1-1  84.4  2.88 ± 0.09 0.94 ± 0.02 1.88 ± 0.02 3.00 ± 0.02 5.66 ± 0.14
ALAD1-2/2-2 15.6  2.81 ± 0.14 0.93 ± 0.03 1.83 ± 0.03 2.90 ± 0.04 5.69 ± 0.22
Non-Hispanic blacks
ALAD1-1 97.4  3.58 ± 0.20 0.97 ± 0.02 1.88 ± 0.01 3.02 ± 0.02* 6.89 ± 0.23
ALAD1-2/2-2 2.6  3.43 ± 0.46 0.87 ± 0.09 1.85 ± 0.08 2.70 ± 0.06 5.86 ± 0.56
Mexican Americans
ALAD1-1  91.2 3.36 ± 0.12 0.91 ± 0.02 1.89 ± 0.02 2.98 ± 0.03 6.37 ± 0.20
ALAD1-2/2-2 8.8  3.14 ± 0.30 0.90 ± 0.04 1.96 ± 0.04 3.11 ± 0.12 6.32 ± 0.63
*p < 0.05.Scinicariello et al.
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or ALAD2-2 genotypes. However, this asso­
ciation was significant only in non­Hispanic 
blacks in the third BLL quartile.
Hypertension. Table 4 shows adjusted 
prevalence odds ratio (POR) for hyperten­
sion for each of the three major race/eth­
nic subgroups in the U.S. population. We 
observed no difference between BLL quartile 
and hypertension in non­Hispanic whites and 
Mexican Americans. However, in the non­
Hispanic black population, individuals in the 
second, third, and fourth BLL quartiles had 
a significant adjusted POR (1.83, 2.38, and 
2.93, respectively) for hypertension compared 
with the lowest quartile. We found no signifi­
cant associations of ALAD and hypertension 
in any of the race/ethnic groups.
Table 5 presents the adjusted PORs 
for hypertension comparing ALAD2 car­
riers and ALAD1 homozygous individuals 
stratified by BLL quartile and by race/eth­
nicity. In the non­Hispanic white popula­
tion, ALAD2 carriers in the highest BLL 
quartile (3.8–52.9 µg/L) had a significantly 
higher POR [2.00; 95% confidence inter­
val (CI), 1.12–3.55] of hypertension than 
did the subjects who were ALAD1 homozy­
gous. Moreover, when we excluded from the 
fourth quartile those with BLL > 10.0 µg/dL, 
we still observed a significant increase in risk 
of hypertension (POR = 1.86; 95% CI%, 
1.00–3.49) (data not shown).
Systolic and diastolic BP. We used multi­
variate linear regression models to assess asso­
ciations with systolic and diastolic BP in each 
race/ethnic group for individuals who were 
not currently taking medications for high BP 
(Table 6). We found a significant interac­
tion between BLL and ALAD in relation to 
systolic BP in two race/ethnic subgroups (p = 
0.04 for non­Hispanic whites, and p = 0.02 
for non­Hispanic blacks). In multivariate 
regression analyses for diastolic BP, the inter­
action between ALAD and BLL was not sig­
nificant in any of the three race/ethnic groups 
(Table 6).
Discussion
Our results for the association of blood 
lead with BP and with hypertension in the 
race/ethnic groups in the U.S. population 
is consistent with previous NHANES III 
studies (Den Hond et al. 2002; Nash et al. 
2003; Vupputuri et al. 2003). Estimates from 
the coefficient regressions for blood lead (Table 
6) predicted that a 2­fold increase of BLL was 
correlated with increases of 1.76 mmHg (95% 
CI, 1.06–2.47) and 0.72 mmHg (95% CI, 
0.19–1.26) in systolic BP for non­Hispanic 
blacks and whites, respectively. Although we 
did not observe an association with BLL and 
hypertension in non­Hispanic whites and 
Mexican Americans, we did find an increased 
prevalence of hypertension in non­Hispanic 
blacks in the second, third, and fourth lead 
quartile compared with those in the lowest 
BLL quartile. A previous evaluation of lead 
levels and hypertension in the NHANES III 
population by Vupputuri et al. (2003) also 
showed that black and white women with BLL 
≥ 5 µg/dL had statistically significantly higher 
odds ratio for having hypertension compared 
with those with BLL < 5 µg/dL.
We found that within the highest quartile 
of lead for the non­Hispanic white population, 
the prevalence of hypertension was significantly 
higher among ALAD2 carriers compared with 
ALAD1 homozygote individuals. In addi­
tion, estimates from regression coefficients of 
the interaction terms shown in Table 6 indi­
cate that, for a doubling of BLL, systolic BP 
increased by an estimated 2.46 mmHg for 
ALAD1-2/2-2 individuals and 0.72 mmHg for 
ALAD1 homozygous individuals for the non­
Hispanic white population. In contrast, for 
non­Hispanic black individuals, for a doubling 
of BLL, systolic BP decreased by an estimated 
4.04 mmHg for ALAD1-2/2-2 individuals and 
increased by 1.76 mmHg for ALAD1 homozy­
gous individuals. This finding may not be reli­
able for non­Hispanic blacks because there 
were substantially fewer ALAD2 carriers in this 
population in our study (n < 50).
Of the two previous studies on ALAD, 
BLL, and BP, one reported an increase in sys­
tolic BP among Korean ALAD2 carriers who 
were occupationally exposed to lead (Lee et al. 
2001), whereas the other reported that ALAD 
was not associated with systolic BP (Smith 
et al. 1995).
The mechanisms of lead­induced hyper­
tension are not well characterized. One 
hypothesis is that lead induces hypertension 
through direct effects on the kidney (Muntner 
et al. 2003). Another hypothesis is that the 
accumulation of lead in the walls of arter­
ies results in arterial stiffness, which induces 
hypertension. Lead has been reported to both 
accumulate in the human aorta (Poklis 1975; 
Schroeder and Tipton 1968) and contribute to 
the increase in pulse pressure that occurs with 
aging (Perlstein et al 2007). Elevated aortic 
stiffness is also known to induce high systolic 
BP and increase pulse pressure (O’Rourke and 
Mancia 1999). Finally, it is also possible that 
lead may alter BP by interference with vascular 
Table 4. Adjusted PORa (95% CI) for hypertension stratified by race/ethnicity.
Variable Non-Hispanic whitesb Non-Hispanic blacksb Mexican Americansb
BLL quartile 
0.7–1.4 µg/dL  Reference Reference Reference
1.5–2.3 µg/dL  1.21 (0.66–2.24) 1.83 (1.08–3.09) 0.74 (0.24–2.23)
2.4–3.7 µg/dL 1.57 (0.88–2.80) 2.38 (1.40–4.06) 1.43 (0.61–3.38)
3.8–52.9 µg/dL 1.52 (0.80–2.88) 2.92 (1.58–5.41) 1.27 (0.59–2.75)
ALAD1-2/2-2  0.76 (0.17–3.50) 3.40 (0.05–219.03) 0.49 (0.08–3.20)
ALAD1-1  Reference Reference Reference
aAdjusted for race/ethnicity, age, sex, BMI, alcohol ingestion, smoking status, education, serum creatinine, serum total 
calcium, glycosylated hemoglobin, and hematocrit. bAdjusted for age, sex, BMI, alcohol ingestion, smoking status, edu-
cation, serum creatinine, serum total calcium, glycosylated hemoglobin, and hematocrit.
Table 5. Adjusted PORa (95% CI) for hypertension by ALAD2 allele within BLL quartiles in the NHANES III 
DNA bank stratified by race/ethnicity.
Characteristic
Quartile 1  
[0.7–1.4 µg/dL  
(n = 1,206)]
Quartile 2  
[1.5–2.3 µg/dL  
(n = 1,263)]
Quartile 3  
[2.4–3.7 µg/dL  
(n = 1,388)]
Quartile 4  
[3.8–52.9 µg/dL  
(n = 1,657)]
Non-Hispanic whitesb 0.78 (0.15–4.08) 1.11 (0.45–2.69) 0.67 (0.39–1.12) 2.00 (1.12–3.55)
Non-Hispanic blacksb 5.71 (0.04–745.01) 3.13 (0.48–20.50) 1.31 (0.29–5.88) 0.60 (0.22–1.63)
Mexican Americansb 0.34 (0.05–2.11) 1.62 (0.43–6.13) 0.94 (0.24–3.73) 0.92 (0.30–2.86)
aAdjusted for race/ethnicity, age, sex, BMI, alcohol ingestion, smoking status, education, serum creatinine, serum total 
calcium, glycosylated hemoglobin, and hematocrit. bAdjusted for age, sex, BMI, alcohol ingestion, smoking status, edu-
cation, serum creatinine, serum total calcium, glycosylated hemoglobin, and hematocrit.
Table 6. Multivariate linear regression models for systolic and diastolic BP for individuals who were not 
currently taking medications for high BP stratified by race/ethnicity (β-coefficient ± SE).a
Non-Hispanic whites Non-Hispanic blacks Mexican Americans
Characteristic Full model p-Value Full model p-Value Full model p-Value
Systolic BP
Ln BLL  1.05 ± 0.37 0.01 2.55 ± 0.49 0.001 0.84 ± 0.46 0.08
ALAD1-2/2-2 –2.14 ± 1.19 0.09 6.85 ± 2.92 0.03 0.84 ± 0.95 0.38
Ln BLL * ALAD1-2/2-2b  2.51 ± 1.16 0.04 –8.41 ± 3.31 0.02 –0.86 ± 1.03 0.41
Diastolic BP
Ln BLL –0.14 ± 0.49 0.77 1.99 ± 0.44 0.0002 0.74 ± 0.38 0.06
ALAD1-2/2-2 –1.18 ± 0.92 0.21 5.36 ± 4.41 0.24 0.89 ± 1.08 0.42
Ln BLL * ALAD1-2/2-2b 0.74 ± 1.08 0.50 –7.20 ± 3.61 0.06 –2.22 ± 1.08 0.052
aAdjusted for age, sex, BMI, alcohol ingestion, smoking status, education, serum creatinine, serum total calcium, glyco-
sylated hemoglobin, and hematocrit. bThe interaction term of Ln BLL and ALAD genotype. ALAD alleles, lead, and hypertension in NHANES III
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signaling pathways. Endothelial nitric oxide 
(NO) regulates vascular function, and the dis­
ruption of the NO activity is important in the 
development of hypertension (Chowdhary 
and Townend 2001). Lead exposure has been 
reported to significantly inhibit endothelial 
NO production (Barbosa et al. 2006), as well 
as to cause NO inactivation by increasing oxi­
dative stress, thereby decreasing NO availabil­
ity (Vaziri and Ding 2001; Vaziri et al. 1999).
There was no association between ALAD2 
carriers and mean BLL in any of the race/eth­
nicities. However, in general, ALAD2 carri­
ers had a lower mean BLL than did ALAD1 
homozygous subjects, although these differ­
ences were not statistically significant. When 
stratified by BLL quartile, only non­Hispanic 
white ALAD2 carriers had a marginally higher 
mean BLL than did ALAD1 homozygous sub­
jects in the fourth BLL quartile. These data 
are in agreement with the view that ALAD2 
allele would significantly affect BLL not at 
low exposure levels but only at higher levels, 
when other lead­binding sites have been satu­
rated (Schwartz et al. 1995; Scinicariello et al. 
2007). Montenegro et al. (2006) reported that, 
although ALAD2 carriers had no significantly 
lower mean BLL than did ALAD1 homozy­
gous individuals, ALAD2 carriers had a sig­
nificantly higher plasma lead level compared 
with homozygous ALAD1 subjects. Therefore, 
it may be possible that non­Hispanic white 
ALAD2 carriers have higher levels of plasma 
lead compared with ALAD1 homozygote indi­
viduals. Consequently, the higher plasma lead, 
interacting with other molecular BP regulatory 
systems, may be responsible for the observed 
increases in systolic BP in ALAD2 carriers.
The present study has several limitations. 
The exclusion from our study of persons who 
reported taking medication for hypertension 
may have diluted the strength and magnitude 
of associations in our analysis for systolic and 
diastolic BP. Second, although we controlled 
for many of the known factors associated with 
BP and hypertension, other variables such as 
serum selenium (Telisman et al. 2001), serum 
zinc (Schwartz 1991), and blood cadmium 
(Navas­Acien et al. 2004) might have influ­
enced our findings. Blood cadmium was not 
measured by NHANES III. However, urinary 
cadmium, a measured variable in NHANES 
III, was not a significant variable for hyperten­
sion or for systolic or diastolic BP (data not 
shown). Urinary cadmium reflects cadmium 
concentration in the renal cortex and is a bio­
marker of both ongoing and long­term cad­
mium exposure, whereas blood cadmium is a 
biomarker of ongoing exposure (Agency for 
Toxic Substances and Disease Registry 1999). 
Therefore, it seems unlikely that including 
blood cadmium in our models would have 
changed our finding. Our results are based on 
BLL; because approximately 95% of the total 
body burden of lead is present in the skeleton, 
a preferred measure of chronic body burden 
would be bone lead (Hu et al. 1996). However, 
the measurement of bone lead in a large sample 
size, such as NHANES, is not feasible, and 
blood lead is known to be associated with bone 
lead (Gwiazda et al. 2005; Todd et al. 2001).
Currently, the CDC designates 10 µg/dL 
as a BLL of concern and has formulated guide­
lines for environmental and educational inter­
vention in children at this level (CDC 2002). 
No corresponding CDC guidance exists for 
BLL measured in adults. However, in the past 
few decades the presence of lead in the envi­
ronment has steadily declined. In the adult 
U.S. population, mean BLL measured in 
NHANES surveys conducted in 1976–1980, 
1988–1991, and 1999–2002 decreased from 
13.1 µg/dL to 3.0 µg/dL and to 01.64 µg/dL, 
respectively (Muntner et al. 2005; Pirkle et al 
1994). This positive and welcome decline has 
steadily continued with a geometric mean 
BLL of 1.41 µg/dL in the U.S. adult popu­
lation ≥ 20 years of age as measured in the 
NHANES survey conducted in 2005–2006 
(Scinicariello F, unpublished data).
Conclusions
We examined the modification by ALAD in 
the association of BLL and BP and hyperten­
sion in the U.S. population. We found that 
within the highest quartile of lead for the non­
Hispanic white population, the prevalence of 
hypertension was significantly higher among 
ALAD2 carriers compared with ALAD1 
homozygotes. In addition, we found that 
ALAD2 carriers in non­Hispanic whites may 
experience a more pronounced effect of lead 
on systolic BP than do homozygous ALAD1 
carriers. These results underscore the impor­
tance of reducing environmental sources of 
lead exposure in the U.S. population, and this 
should remain a major public health prior­
ity based on consistent evidence of increased 
health risks (Kosnett et al. 2007; Schwartz 
and Hu 2007). Given the high frequency of 
ALAD2 carriers (15.6%) in the non­Hispanic 
white population, and the cross­sectional 
nature of the present study, prospective studies 
are needed to confirm and elucidate the role of 
ALAD polymorphism and these associations.
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